A prospective randomized study assessing safety and efficacy of low-dose cytomegalovirus prophylaxis with Valganciclovir and Valaciclovir regimen in renal transplant recipients

Trial Profile

A prospective randomized study assessing safety and efficacy of low-dose cytomegalovirus prophylaxis with Valganciclovir and Valaciclovir regimen in renal transplant recipients

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Nov 2017

At a glance

  • Drugs Valaciclovir (Primary) ; Valganciclovir (Primary)
  • Indications Cytomegalovirus infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 17 Nov 2017 New trial record
    • 27 Sep 2017 Results presented at the 18th Congress of the European Society for Organ Transplantation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top